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The PE_PGRS33 protein is a member of the PE family, which encompasses the PE and the
PE_PGRS subfamilies. Among PE_PGRS’s, this protein is one of the most studied antigens
and its immunomodulatory properties are influence by both PE and PGRS domains. How-
ever, the contribution of these domains to the host immune recognition of the PE_PGRS33
protein and their potential role in latent tuberculosis infection in humans is still unknown.
In this study, the immunogenic properties of the complete PE_PGRS33 protein and each
domain separately were evaluated in BALB/c mice and latent tuberculosis infected (LTBI)
humans. In mice, PE_PGRS33 and its domains induced similar antibody production and
secretion of IFN-γ. PE_PGRS33 and the PE domain stimulated higher CD4+ and CD8+
T-cell proliferation compared to the PGRS domain. This demonstrated that the principal
difference in the immune recognition of the domains is the higher activation of T-cell sub-
populations involved in the control of tuberculosis. In humans, the secretion of IFN-γ in
response to PE_PGRS33 was detected in both LTBI and in non-infected vaccinated indi-
viduals. The same was observed for antibody response, which targets epitopes located
in the PGRS domain but not in the PE domain. These observations suggest that T and B
cell responses to PE_PGRS33 are induced by BCG vaccination and can be maintained for
many years in non-infected individuals.This also indicates that the IFN-γ response detected
might not be associated with latent tuberculosis infection. These results contribute to the
elucidation of the role of the PE_PGRS33 protein and its PE and PGRS domains in the
immune response against Mycobacterium tuberculosis.
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INTRODUCTION
Mycobacterium tuberculosis, the causative agent of human tuber-
culosis, is one of the most successful pathogens known. This
bacterium is able to elude the host immune system and starts
the disease after the infection or remains latent during long time
(1). Many factors that could explain these characteristics were
elucidated after the genome sequencing of the M. tuberculosis
H37Rv (2). The genome sequence of these bacteria also revealed
the presence of the PE family, which encompasses the PE and
PE_PGRS subfamilies with about 100 genes scattered throughout
the genome. Around 61 of these genes encodes for members of the
PE_PGRS subfamily. These proteins are characterized by a highly
conserved PE domain of approximately 110 amino acid residues
that contains the motif Pro–Glu (PE) near the N-terminus. This
domain is followed by the PGRS (polymorphic GC-rich-sequence)
domain, which varies in size from 100–1400 amino acid residues
and is rich in repetitive Gly–Gly–X motifs (2).
Some PE_PGRS proteins are exposed at the bacterial surface,
where they can interact with the host immune system (3–5). Anti-
bodies against PE_PGRS51, PE_PGRS62, PE_PGRS33, and the
PGRS domain of Wag22 (Rv1759cPE_PGRS) are present in sera from
patients with tuberculosis or during experimental tuberculosis in
mice (6–10). Several PE_PGRS elicit T-cell responses in humans
and are recognized by major histocompatibility complex-I (MHC-
I)-restricted CD8+ T cells in mice, suggesting that many members
of the PE_PGRS subfamily are highly immunogenic (11, 12).
PE_PGRS proteins are also involved in latency. Mutations in
pe_pgrs genes of other mycobacterial species have shown decreased
persistence in granulomas (13). The PE_PGRS33 protein is a
member of the PE_PGRS subfamily that stimulates tumor necro-
sis factor-α (TNF-α) production, one of the cytokines involved
in the induction and maintenance of latent tuberculosis infec-
tion in animal models mimicking human latency (14–16). The
Rv1759cPE_PGRS antigen induces immune response maintaining
the latent infection in a murine model of chronic tuberculosis (17).
M. tuberculosis clinical strains harboring big genetic variations in
the rv1818c that codifies the PE-PGRS33 have been associated
with clustering of tuberculosis cases and absence of cavitations
in the lungs. This suggests that this protein plays a role in the
establishment or maintenance of latent infection (18). Until now,
the immune response against the PE_PGRS proteins has not been
described in M. tuberculosis latent-infected individuals.
Additionally, the PE_PGRS33 protein plays an important and
may be non-redundant role in the pathogenesis of M. tuberculosis
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(19). The sequence of the PE domain of this protein is highly
conserved among M. tuberculosis clinical isolates (18, 20). This
domain directs the cell wall localization of PE_PGRS33 (21). It
has been reported that mutations in the PE domain affect the
pro-inflammatory properties of the protein (22). On the other
hand, the PGRS domain exhibits the major sequence variations
in clinical M. tuberculosis strains (20). The PGRS fragment medi-
ates the interaction with toll-like receptor 2 (TLR2) triggering
host-cell death (14, 22). Deletions inside this domain can mod-
ulate the secretion of TNF-α induced by the PE_PGRS33 (14).
The immunogenic properties of the PE domain have been eval-
uated in a murine model (9). The contribution of the PGRS
domain to the immune response generated by PE_PGRS33 has
been inferred from the study of the complete protein and the PE
domain. However, the effect of the PGRS single domain has not
been reported.
In this work, the immunogenic properties of the PE_PGRS33
protein and the PE and PGRS domains were studied in mice.
This study was extended to humans where the secretion of IFN-γ
and antibodies levels in latent tuberculosis-infected (LTBI) and
non-infected individuals were evaluated.
MATERIALS AND METHODS
PREPARATION OF ANTIGENS
Cloning the PE and PGRS domains of PE_PGRS33
The full-length rv1818c gene, which codifies for the PE_PGRS33
was cloned into the pET15b vector (Novagen Inc., Madison, WI,
USA) fused to a histidine (His) tag was kindly provided by Dr. M.
J. Brennan [CBER, FDA, Bethesda, MD, USA (13)]. The rv1818c
gene from pET15b was inserted into the plasmid pcDNA3 (Invit-
rogen, Carlsbad, CA, USA). An 1172 bp fragment (from nucleotide
339 to 1494) encoding the PGRS region of the rv1818c gene
was amplified by PCR from pcDNA3 using the forward primer
5′-GGAATTCCATATGGGGCGCCCACTGATCGGT-3′ (which
includes an NdeI site) and the reverse primer 5′-ATGGATCCCTAC
GGTAACCCGTTCATCCCGTTC-3′ containing a BamHI site
and a stop codon. The NdeI–BamHI fragment was then
cloned in pET15b. The PE coding region of the rv1818c
gene (from nucleotide 1 to 339) was amplified using the for-
ward primer 5′-CGGGATCCATGTCATTTGTGGTCACGATCC-
3′ holding a BamHI site and the reverse primer 5′-
CGGAATTCACAACAGCGCCAGGGCG-3′ including an EcoRI
site and a stop codon. The EcoRI–BamHI fragment was then
cloned into the multiple cloning site of the plasmid pGEX-
4T-2 (Amersham Pharmacia, Piscataway, NJ, USA) to create
a fusion product with the coding sequence for glutathione
S-transferase (GST).
Expression and production of PE_PGRS33, PE, and PGRS domains
PE_PGRS33 and its PGRS domain were expressed in Escherichia
coli C41 (DE3). Bacteria were cultivated at 37°C in Luria–Bertani
broth with 100µg/ml ampicillin. All the chemicals were obtained
from SIGMA Aldrich, St. Louis, MO, USA unless otherwise
stated. Protein expression was induced with 0.5 mM isopropyl-β-
d-thiogalactopyranoside (IPTG) at OD= 0.6. Cells were harvested
by centrifugation, resuspended in phosphate-buffered saline (PBS)
with 1× complete ethylenediaminetetraacetic acid (EDTA)-free
protease inhibitor (Roche Applied Science, Mannheim, Germany),
and disrupted by sonication. After centrifugation, the inclusion
bodies were washed sequentially with 2% Triton X-100, 1% Tri-
ton X-100, and PBS. The inclusion bodies were dissolved in buffer
A [50 mM Na2HPO4 (pH 8.0), 8 M urea, 300 mM NaCl, 10 mM
Imidazole] at 4°C for 14 h. The PE_PGRS33 protein was purified
by metal affinity chromatography in an Akta-Prime (GE Health-
care Biosciences, Pittsburgh, PA, USA). The solution of proteins
was bound to a His–Trap HP column (GE Healthcare Biosciences,
Pittsburgh, PA, USA) previously equilibrated with buffer A. The
protein elution was performed using 500 mM Imidazole in buffer.
The purified protein was dialyzed and buffer was exchanged for
50 mM Tris–HCl (pH 8.0), 150 mM NaCl.
The PE domain fusion to GST was expressed in E. coli BL21
(DE3) grown in Luria–Bertani broth with 100µg/ml carbenicillin
at 37°C. Protein expression was induced with 0.25 mM IPTG at
OD= 0.6. Cells were harvested by centrifugation and disrupted
by sonication. Inclusion bodies were dissolved in 50 mM Tris–HCl
(pH 8.0), 150 mM NaCl, 8 M urea, 1 mM dithiothreitol (DTT),
1 mM EDTA. The supernatant was dialyzed against 50 mM Tris–
HCl (pH 8.0), 100 mM NaCl, and 1 mM DTT (union buffer)
containing 4 and 2 M urea in sequential steps. The final dialy-
sis step was performed against union buffer. A final concentration
of 1% Triton X-100, 20µg/ml PMSF, and 1 mM EDTA was added
to the dialyzed sample. The suspension was bound to glutathione
agarose at 0.5 ml resin per 2 ml sample by the batch method with
gentle agitation at 4°C for 12 h. The resin was washed with 20
bed volumes of union buffer/1% Triton X-100 and then with 20
bed volumes of union buffer. The PE protein was eluted by incu-
bation with elution buffer [50 mM Tris–HCl (pH 8.0), 100 mM
NaCl, and 20 mM reduced glutathione] at 4°C for 90 min. The
glutathione was removed by dialysis against 50 mM Tris–HCl (pH
8.0), 100 mM NaCl.
MURINE MODEL
Preparation of PE_PGRS33 for the immunization of mice
A total amount of 100µg of recombinant PE_PGRS33 was
resolved in 12% polyacrylamide gels containing SDS according
to the discontinuous buffer system of Laemmli (23). Proteins
were transferred to nitrocellulose membranes (Amersham Phar-
macia, Piscataway, NJ, USA). The protein band was identified by
temporary staining with Ponceau S solution. The portion of the
membrane with the identified protein was cut and converted into
antigen-bearing particles using a previously described method
(24). Briefly, the protein band was excised from the nitrocellulose
sheet, cut in small pieces, and dissolved in dimethyl sulfoxide. The
PE_PGRS33-bearing nitrocellulose was precipitated with 0.05 M
carbonate/bicarbonate buffer (pH 9.6). After washing three times
with PBS, the product was resuspended in 500µl of sterile PBS.
Nitrocellulose particles without protein were prepared under same
conditions to be used as control. This methodology minimized the
presence of undesirable proteins allowing the immunization to be
performed only with the protein of interest.
Immunization of mice
The 6–7 weeks old female BALB/c mice were obtained from
Harlan, Mexico. These mice were housed under standard
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pathogen-free conditions. All animal studies were carried out
in strict accordance with the recommendations from the cur-
rent Institutional Guidelines for the Care and Use of Laboratory
Animals. The animal study was previously approved by the Com-
mittee for the Care and Use of Laboratory Animals of Instituto de
Investigaciones Biomédicas. Two groups of mice (n= 4 per group)
were used in each of three independent experiments. Mice were
immunized by intraperitoneal injection of 20µg of recombinant
PE_PGRS33 on antigen-bearing nitrocellulose (100µl of PBS con-
taining 20µg of protein per mouse). Control mice received 100µl
of PBS containing only nitrocellulose particles by the same route.
Intraperitoneal booster injections with same amount of antigen-
bearing nitrocellulose were administered on days 21 and 42 to
immunized mice. Control mice were injected with nitrocellulose
particles on days 21 and 42.
Carboxyfluorescein diacetate succinimidyl ester proliferation assay
Spleen cells were obtained from immunized and control mice
2 weeks after the last immunization. Cells were extracted by tissue
disruption and suspended in RPMI 1640 medium. All chemicals
were obtained from GIBCO, Gran Island, NY, USA, unless oth-
erwise stated. The erythrocytes were lysed by mixing the cells
with 0.15 M ammonium chloride (NH4Cl), 1.5 mM buffer HEPES
(SIGMA Aldrich, St. Louis, MO, USA), 1 mM sodium bicarbon-
ate (NaHCO3) at room temperature for 5 min. The reaction
was stopped by adding 10 volumes of Dulbecco’s PBS (DPBS).
Later 107 splenocytes were incubated at room temperature in
the dark with 0.5µM carboxyfluorescein diacetate succinimidyl
ester (CFSE, Invitrogen, Carlsbad, CA, USA) for 5 min. The reac-
tion was stopped by adding nine volumes of RPMI 1640 plus
10% fetal bovine serum (FBS). CFSE-stained cells were cen-
trifuged at 1500 rpm for 5 min, washed twice in DPBS with
10% FBS, and resuspended in RPMI supplemented with 10%
FBS, 1.5 mM glutamine, 100 U/ml penicillin, 100µg/ml strep-
tomycin, 1% non-essential amino acids, 20 mM HEPES buffer,
and 50µM 2-mercaptoethanol. Viable cells were counted by try-
pan blue exclusion, and 1.5 million cells were stimulated with
25µg of PE_PGRS33, PE, PGRS, or GST protein plus 10µg/ml
of polymyxin B (Calbiochem, Pacific Center, CA, USA) in 24-
well plates at 37°C in 5% CO2 for 96 h. Polymyxin B was added
to rule out the possibility of contamination with lipopolysac-
charide (LPS). As positive control, 1.5 million CFSE-labeled
spleen cells from control and immunized mice were stimulated
with 2µg/ml of concanavalin A (SIGMA Aldrich, St. Louis,
MO, USA) at 37°C in 5% CO2 for 72 h. The cells were har-
vested, washed with DPBS with 2% FBS and 0.09% sodium
azide (NaN3), and incubated with an anti-mouse FcγR antibody
(CD16–CD32, CALTAG, Burlingame, CA, USA) diluted 1:500 to
block the non-antigen-specific binding of conjugated antibod-
ies. CFSE-labeled cells were then incubated with phycoerythrin-
conjugated anti-CD4 antibody (BD Pharmingen, San Diego, CA,
USA) diluted 1:200 and allophycocyanin-conjugated anti-CD8
antibody diluted 1:200 (CALTAG, Burlingame, CA, USA) on ice
for 15 min. The cells were washed with DPBS with 2% FBS and
0.09% NaN3 and resuspended in 0.5 ml DPBS. Three-color flow
cytometry was performed in a fluorescence-activated cell sort-
ing (FACS) Calibur cytometer (BD, Mountain View, CA, USA).
Lymphocytes and blasts were identified by forward scatter (FCS)
and side scatter characteristics (SSC) in 10,000 events acquired.
The percentage of proliferating cells was determined by gating
on CD4+ or CD8+ cells and comparing the proliferating popu-
lation (CFSEdim) with lineage positive cells that had not divided
(CFSEbright). Cellquest™ software was used to acquire and ana-
lyze the data. Samples and controls were analyzed under same
conditions.
Mouse cytokine assay
The supernatants from mice cultured spleen cells used in the
CFSE proliferation assay were evaluated for IFN-γ production
using a Murine IFN-γ ELISA development kit (PEPROTECH,
Mexico City, Mexico) following the instructions of manufacturer.
Briefly, ELISA plates containing 1µg/ml capture antibody per well
were incubated at 4°C overnight. After addition of standards and
samples, plates were incubated at room temperature for 2 h. The
detection was performed with 0.5µg/ml detection antibody. The
plates were incubated at room temperature for 2 h. Avidin peroxi-
dase diluted 1:2000 was added and incubated at room temperature
for 30 min. A color reaction was developed using ABTS liquid sub-
strate and absorbance values were measured at 405 nm using an
ELISA plate reader.
Antibody detection in mice
Two weeks after the last immunization blood was collected from
the tail veins of the immunized and control mice. The titers of
Immunoglobulin G (IgG), IgG1 and IgG2a in sera were deter-
mined using the ELISA assay. Briefly, 96-well plates (Maxisorp
Nunc Immunoplates) were coated with 5µg/ml of recombinant
PE_PGRS33, PE, PGRS, or GST at 4°C overnight. The plates
were blocked with bovine serum albumin (BSA. SIGMA, St.
Louis, MO, USA) and incubated with different dilutions of the
mouse sera (3× 102–1× 105). Goat anti-mouse IgG–horseradish
peroxidase (HRP) conjugate, IgG1–HRP and IgG2a–HRP anti-
body (all from ZYMED, San Francisco, CA, USA) were used as
secondary antibodies. A color reaction was developed with o-
phenylenediamine tetrahydrochloride (SIGMA, St. Louis, MO,




All the 88 volunteers who participated in this study were gradu-
ate students from the School of Dentistry, Universidad Nacional
Autónoma de México. All participants had been vaccinated with
Mycobacterium bovis Bacillus Calmette–Guérin (M. bovis BCG)
when infants. The individuals were between 25 and 32 years old,
clinically healthy, and had chest radiography negative for tuber-
culosis. The study in humans was performed in accordance with
the Guidelines for Scientific Research with Humans of the Insti-
tuto de Investigaciones Biomédicas. The protocol was previously
approved by the Ethics Committee of the same Institute. All par-
ticipants signed consent forms detailing all relevant information
about the nature of the study. All individuals participated volun-
tarily and their identities will remain undisclosed. No incentives
were offered to participants.
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IFN-γ release assay to detect LTBI and non-infected individuals
Blood samples were collected in heparinized tubes from each
of the 88 participants. Aliquots of 1 ml of heparinized blood
were incubated in the presence of the QuantiFERON®-TB Gold
Kit (Cellestis Limited, Carnegie, VIC, Australia) antigens ESAT-
6, CFP-10, and mitogen in 24-well tissue culture plates at 37°C
in 5% CO2 for 16 h. Plasma was obtained by centrifugation
and the samples were evaluated for IFN-γ production using the
Human IFN-γ ELISA kit provided with the QuantiFERON®-
TB Gold Kit following the instructions of manufacturer. Briefly,
human IFN-γ standards and plasma samples were added to 96-
well microplates coated with murine anti-human IFN-γ. The
conjugate murine anti-human IFN-γ HRP was incorporated
immediately after samples, standards, and conjugates were thor-
oughly mixed in a microplate shaker and incubated at room
temperature for 2 h. After the addition of the enzyme sub-
strate solution, the plate was incubated at room temperature
for 30 min. The reaction was stopped with enzyme stopping
solution. The optical density was read after 5 min using a
microplate reader. The results were analyzed using the Quan-
tiFERON® Analysis software. The results of this analysis were
used to divide the group of participants as LTBI and non-infected
individuals.
IFN-γ release assay to detect responders to the PE_PGRS33
complete protein
An aliquot of 1 ml of heparinized blood obtained from each of the
88 participants was incubated with 25µg/ml of PE_PGRS33 in 24-
well tissue culture plates at 37°C in 5% CO2 for 16 h. Plasma was
obtained by centrifugation and the samples were evaluated for
IFN-γ production using the Human IFN-γ ELISA kit provided
with the QuantiFERON®-TB Gold Kit following the instructions
of manufacturer, as above described. The results of this assay iden-
tified responders to the complete PE_PGRS33 protein among the
LTBI and non-infected individuals.
IFN-γ release assay to study the response to the PE_PGRS33 protein
and its PE and PGRS domains in LTBI and non-infected individuals
A volume of 5 ml of blood was collected in heparinized tubes
and diluted 1:10 with RPMI 1640 medium supplemented with
2 mM glutamine, 100 U/ml penicillin, and 100µg/ml strepto-
mycin (all from GIBCO BRL). An aliquot of 1 ml of diluted blood
was incubated in a 24-well plate with 25µg of PE_PGRS33, PE,
PGRS, or GST protein plus 10µg/ml polymyxin B at 37°C in
5% CO2 for 6 days. The concentration of IFN-γ in supernatants
was quantified using the Human IFN-γ ELISA kit provided with
the QuantiFERON®-TB Gold Kit according to the instructions of
manufacturer, as above described.
Antigen-specific antibody detection in LTBI and non-infected
humans
Antibodies against PE_PGRS33 and their domains were detected
in 63 out of 88 sera of the individuals by ELISA assay. This assay
was carried out as above described for antibody detection in mice
with the following modifications: human sera were diluted 1:100,
1:300, and 1:500. All samples were incubated with anti-human IgG
HRP conjugate. In addition, three samples from LTBI and four
from non-infected individuals that produce IFN-γ in response to
PE_PGRS33 were also tested with IgG1 HRP conjugates (Caltag,
Burlingame, CA, USA). The color reaction was developed with
o-phenylenediamine tetrahydrochloride. Absorbance values were
measured at 492 nm using an ELISA plate reader.
STATISTICAL ANALYSIS
Data between groups were compared using the Mann–Whitney U
test at the 0.05 significance level.
RESULTS
HUMORAL AND CELLULAR IMMUNE RESPONSE TO PE_PGRS33, THE
PE, AND PGRS DOMAINS IN MICE
Humoral immune response in mice
Sera from immunized and control mice were tested using ELISA
assay to determine the levels of antigen-specific IgG antibod-
ies against PE_PGRS33 and its PGRS and PE domains. Similar
titers of IgG were observed in both immunized and control mice
(Figure 1A). Titers of IgG1 and IgG2a were quantified to identify
the differences between these IgG subclasses. Similar titers of IgG1
against the complete protein and its domains were detected in all
dilutions tested (Figure 1B). In contrast, the levels of IgG2a sub-
class against the PE domain were lower than the levels against the
PGRS domain or the complete PE_PGRS33 protein (Figure 1C).
This indicated that IgG1 antibodies in sera from the immunized
mice targeted the complete PE_PGRS33 and its domains, whereas
the IgG2a antibodies recognized epitopes located exclusively in the
PGRS domain.
Antigen-specific T-cell proliferation in mice
The proliferation of CD4+ and CD8+ T cells was measured in
splenocytes of the mice immunized with the PE_PGRS33 protein
to determine the contribution of PE_PGRS33 and its PE and PGRS
domains to the activation of T cells (for flow cytometry histograms,
see Figure S1 in Supplementary Material). The PE_PGRS33 com-
plete protein similarly activated the proliferation of CD4+ and
CD8+ T cells (Figure 2). Both the PE and PGRS domains stimu-
lated the proliferation of CD4+ and CD8+ T cells. However, the
response of the two cell subpopulations against the PE domain was
significantly higher than that from the PGRS domain (Figure 2).
The proliferative responses of lymphocytes from the control and
immunized mice were statistically different (Figure 2). The GST
co-expressed as a fusion product with the PE domain did not
impact cell proliferation (Figure 2).
INF-γ secretion in mice
The PE_PGRS33 protein, the PE, and PGRS domains induced sig-
nificantly higher IFN-γ responses compared with unstimulated
cells (Figure 3). The concentration of IFN-γ in the immunized
mice was also higher than that from the controls (Figure 3).
The levels of INF-γ secretion after stimulation with PE_PGRS33
and the domains were similar (Figure 3). This indicated that the
PE_PGRS33, the PE, and PGRS domain are inducers of cellular
immune response in mice.
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FIGURE 1 | Humoral immune response to PE_PGRS33, PGRS, and PE in
immunized mice. BALB/c mice were immunized with PE_PGRS33 and
sera were collected 15 days after the last immunization. IgG (A), IgG1
(B), and IgG2a (C) responses to PE_PGRS33 (), PE (N), PGRS (©), and
the control protein GST (), were evaluated by ELISA assay. For total IgG
determination, each serum was diluted 1:100 and for IgG1 and IgG2a
determination, mice sera were diluted as indicated in the figure. Bars
(A) and datum points (B,C) are the average readings±SD of data from four
mice in the group, and the results showed are representative of three
independent experiments.
IMMUNE RESPONSE IN HUMANS
INF-γ responses to the complete PE_PGRS33 protein in LTBI and
non-infected individuals
From the 88 individuals that participated in the study, 14 were
identified as LTBI and 74 as non-infected (Table 1). To determine
whether PE_PGRS33 is inducing an immunological response in
humans, the secretion of IFN-γ by whole blood cells stimulated
with the PE_PGRS33 protein was measured. The results obtained
showed that the blood cells from 28.5% of LTBI secreted IFN-γ
in response to the PE_PGRS33 compared to the 21.6% from the
non-infected individuals (Table 1). This suggests that the IFN-γ
response to the PE_PGRS33 protein is not associated with latent
tuberculosis infection.
FIGURE 2 | Antigen-specific proliferation of CD4+ and CD8+ T cells in
immunized mice. Splenocytes from PE_PGRS33-immunized mice were
stained with CFSE and incubated with 25µg of PE_PGRS33, PGRS, PE, or
GST protein plus 10µg of Polymyxin B for 4 days. Spleen cells from mice
injected with only nitrocellulose were also cultured with antigens (control).
Cells without the antigens were incubated for the same length of time
(unstimulated). Splenocytes were then labeled with anti-CD4-phycoerythrin
(A) or anti-CD8-allophycocyanin (B) monoclonal antibodies and the
percentage of proliferating cells were determined by CFSE dilution and flow
cytometry. Each bar represents the mean±SD of data from four mice per
group, and the results are representative of those obtained from three
independent experiments.
FIGURE 3 | Antigen-specific IFN-γ secretion in immunized mice. Spleen
cells from mice immunized with PE_PGRS33 or from control mice were
incubated with 25µg of PE_PGRS33, PGRS, PE, or GST recombinant
purified proteins plus 10µg/ml of polymyxin B for 4 days. The culture
supernatants were evaluated for IFN-γ production using ELISA assay. Each
bar represents the mean±SD of data from four mice per group.
Representative results of three independent experiments are shown.
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Table 1 | IFN-γ release assay to detect responders to the PE_PGRS33





% IFN-γ response to
PE_PGRS33
Positive Negative
LTBI 14 (4/14) 28.5 (10/14) 71.5
Non-infected 74 (16/74) 21.6 (58/74) 78.4
INF-γ response to PE_PGRS33 and its PE and PGRS domains in LTBI
and non-infected individuals
From the 20 individuals (4 from LTBI and 16 from non-infected)
that showed positive IFN-γ response to the PE_PGRS33 protein,
only 7 were further tested for immune response to the PE and
PGRS domains (Table 1). This group of participants that agreed
to continue participating in the study included three LTBI and
four non-infected individuals.
The secretion of IFN-γ in response to the PE_PGRS33 pro-
tein and its PE and PGRS domains was quantified in whole blood
cells from the seven participants with positive IFN-γ response to
PE_PGRS33. The results indicated a higher secretion of IFN-γ in
response to the PE_PGRS33 protein in non-infected individuals
than in LTBI individuals (Figure 4). A tendency for IFN-γ secre-
tion to be higher in response to the PE domain than the PGRS
domain was observed (Figure 4).
Antigen-specific humoral immune response in LTBI and
non-infected humans
The serum from each of the seven individuals from LTBI and
from non-infected individuals that produce IFN-γ in response to
PE_PGRS33 was tested for antibody response using the ELISA
assay. Human anti-IgG and IgG1 antibodies were used to detect
specific antibodies against the PE_PGRS33 protein and its PE and
PGRS domains. The IgG response against the PE domain was sig-
nificantly lower compared to that from the PE_PGRS33 complete
protein in the non-infected (p< 0.05) and in the LTBI individu-
als (p< 0.05) (Figure 5A). The IgG response against the PE was
lower than that from the PGRS (p< 0.05) in non-infected indi-
viduals. On the other hand, the IgG response against the PE was
as low as the response against the negative control (GST) in the
LTBI individuals (Figure 5A). The IgG1 response against the PE
domain was significantly lower than that against the PGRS domain
and the PE_PGRS33 protein in non-infected and LTBI individuals
(Figure 5B).
Furthermore, levels of IgG against PE_PGRS33 and their PGRS
and PE domains were detected by ELISA in 63 sera from LTBI
and non-infected individuals. Based in the above assay, only indi-
viduals with OD 600 nm over 0.3 were considered to have a
significant amount of antibodies. It is worth of note, that 58.4% of
non-infected individuals showed antibodies against the complete
protein and a higher number of sera 66.6% recognized the PGRS
domain. Results are shown in Table 2.
Together these results indicated that the humoral immune
responses against PE_PGRS33 targets epitopes mainly located in
the PGRS domain.
FIGURE 4 | INF-γ response to the PE_PGRS33 and its PE and
PGRS domains in LTBI and non-infected individuals. Diluted
whole blood cells were stimulated with 25µg of PE_PGRS33, PE,
PGRS, or GST protein plus 10µg/ml of polymyxin B for 6 days. IFN-γ
in the supernatants was quantified using the Human IFN-γ ELISA kit
provided with the QuantiFERON®-TB Gold Kit. Letters represent
each individual tested and symbols correspond to the amount of
IFN-γ produced by each of them.
DISCUSSION
The PE_PGRS33 protein has been involved in the pathogenesis
of M. tuberculosis (18) and it is known that the PE domain is
required for the protein translocation through the mycobacter-
ial cell wall and the induction of primary necrosis (21, 25). The
PGRS domain interacts with the TLR2-inducing apoptosis, tar-
gets the mitochondria triggering necrosis, and is responsible of
the immunomodulatory properties of the entire protein (14, 22,
25). Even though the mentioned characteristics of the PE and
PGRS domains have been elucidated, their contribution to the
immunogenicity of the complete PE_PGRS33 protein has not been
described.
In this study, the immunization of mice with the PE_PGRS33
protein stimulated CD4+ and CD8+ T-cell proliferation as well
as IFN-γ secretion. This indicated that PE_PGRS33 is highly
immunogenic. These results agreed with previous reports describ-
ing the immunogenic properties of the PE_PGRS33 (12). The
CD4+ and CD8+ T cells are crucial in the protective host response
against M. tuberculosis. These T-cell subsets migrate to the site
of infection to produce the cytokines involved in the control of
the disease (26, 27). The proliferation of CD8+ T cells caused
by the immunization with the gene rv1818c, which codifies for
PE_PGRS33 has been reported (12). The activation of CD4+
T cells in response to PE_PGRS33 presented in this work con-
tribute to the knowledge of T cells subpopulations involved in the
immunological response against this protein. These findings sup-
port the potential use of PE_PGRS33 as a vaccine candidate for
tuberculosis (12).
The absence of secretion of IFN-γ in response to the full-length
PE_PGRS33 protein has been reported in C57Bl/6 mice (9). In
contrast, high concentrations of IFN-γ secreted using BALB/c

























































Cohen et al. Mycobacterium tuberculosis, PE_PGRS33, and their domains
FIGURE 5 | Antigen-specific antibody response in LTBI and non-infected
individuals. Sera from LTBI and non-infected vaccinated individuals were
diluted 1:300 and incubated with PE_PGRS33, PE, PGRS, and the control
protein GST. Antigen-specific IgG (A) and IgG1 (B) were evaluated by ELISA.
Letters in legend represent each individual tested and symbols correspond to
OD readings. Mean values are showed as horizontal bars.
Table 2 | IgG levels against PE_PGRS33 and their PGRS and PE





% Individuals with IgG levels
over 0.3 of OD 600 nm
PE_PGRS PGRS PE
LTBI 10 (2/10) 2 (4/10) 4 (0/10) 0
Non-infected 53 (31/53) 58.4 (35/53) 66.06 (0/53) 0
Sera from LTBI and non-infected vaccinated individuals were diluted 1:300.
mice were obtained. These results agreed with those published
by Chaitra et al. (12) in same mice strain. The BALB/c mice were
immunized with protein in the present study, while DNA and
DNA prime-protein boosted were used in published works (12).
Therefore, the immunization method does not explain the con-
trasting results. Such discrepancy is probably due to the dissimilar
strains of mice used. This indicates that differences in the MHC
might have an impact in the immune recognition of the PE_PGS33
protein.
The results of the cellular immune response in mice indicated
that the PE and PGRS domains triggered the proliferation of CD4+
and CD8+ T cells. In agreement, Chaitra et al. (12) reported epi-
topes in the PE and PGRS domains presented to MHC-I and
inducing effectors functions in CD8+ T cells. A MHC-II-restricted
epitope found in the PE_PGRS53 is capable of stimulating CD4+
T-cell responses in human reactors to PPD (28). A comprehen-
sive analysis of MHC-II epitopes has not been performed in
PE_PGRS33. However, the activation of CD4+ T cells observed in
this work suggested that both domains carry peptides inducers of
MHC-II-dependent responses. According to the results obtained,
both domains stimulated comparable IFN-γ secretion levels while
the PE domain was the main inducer of proliferation of CD4+
and CD8+ T cells. This suggested that the PE domain could be
stimulating a higher proliferation rate in these subpopulations
to perform other functions besides the production of IFN-γ, as
described previously (27).
When the PE_PGRS33 was used as immunogen in mice, the
induced IgG levels to the full-length protein and to its domains was
very similar. A possible explanation to this observation could be
that when the domains are separated, they lose their original con-
formation and expose cryptic epitopes that are recognized by the
antibodies generated in the immunized animal. On the other hand,
in the complete protein these antigenic determinants remain hid-
den. This demonstrated that both domains are as highly antigenic
as the entire protein in mice. The levels of IgG subclasses were fur-
ther analyzed to detect differences in response to the domains stud-
ied. The IgG2a antibodies were directed to the complete protein
and the PGRS domain whereas the IgG1 targeted all three antigens.
The titration of these IgG subclasses revealed higher IgG1 levels
than IgG2a. This showed that the IgG2a response is masked by the
high IgG1 titer, which is the mayor contributor to the total IgG.
These results indicated that PE and PGRS are antigenic in BALB/c
mice with differences in the recognition at IgG subclass levels.
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The role of some PE_PGRS proteins in mycobacterial per-
sistence has been described (13, 17, 18). The identification of
antigens interacting with the immune system during the latent
infection will be essential in the development of immunological
markers for this particular condition. One of the hypotheses of
the present study was that PE_PGRS33 could be an important
antigen in M. tuberculosis latency in humans. For this reason, a
cellular immune response to PE_PGRS was expected in LTBI indi-
viduals. The results obtained in humans indicated that the IFN-γ
response to the PE_PGRS33 protein might not be associated with
latent tuberculosis infection. The high number of LTBI individu-
als with negative response to the PE_PGRS33 might be explained
by the possible infection with strains not expressing rv1818c gene.
Another reason could be the infection by strains containing large
variations in the gene sequence. This genetic variation would result
in significant changes in the PE_PGRS33 leading to the non-
recognition by the immune system. Both mechanisms have been
described to be a source of polymorphism for PE_PGRS members
in clinical isolates of M. tuberculosis (20, 29–32).
The IgG1 subclass has been reported to be the predominant iso-
type in tuberculosis infection (33). For this reason, the humoral
immune response to the PE_PGRS33 protein and the PE and PGRS
domains was evaluated in LTBI and non-infected individuals by
determination of total IgG and IgG1. The results showed that
the antibody response was directed against the PE_PGRS33 pro-
tein targeting specifically the PGRS domain. The PGRS domain
of PE_PGRS33 is rich in Gly–Gly–Ala–Gly–Gly repeats. These
sequences could be the target of the antibody response observed in
this study because proteins with repetitive amino acid sequences
have been identified as immunodominant in rabbits and humans
(7). In agreement, the PE_PGRS62 protein induced a strong anti-
body response against the full-length protein and a weak response
to its PE domain in LTBI and non-infected humans (8). This sup-
ports the pattern of antibody recognition observed in this study for
PE_PGRS33. The antibody response to the PE_PGRS33 in non-
infected individuals can be attributed to M. bovis BCG vaccination.
This indicates that sera reactivity to this protein in healthy indi-
viduals is independent of the infection with M. tuberculosis. In the
PE_PGRS33 responders who participated in the second stage of
the study, the cellular immune recognition of PE_PGRS33 showed
a tendency to be higher in non-infected individuals compared with
LTBI individuals. For the protein domains a clear tendency was not
observed. In studies involving large populations a more evident
trend might be obtained.
In conclusion, it was demonstrated that the PE and the PGRS
domains have a role in the cellular and humoral immune response
stimulated by the PE_PGRS33 protein in BALB/c mice. The
PE_PGRS33 also induced the activation of T-cell subpopula-
tions involved in the control of tuberculosis and secretion of
IFN-γ. This confirmed the potential use of the PE_PGRS33 pro-
tein as candidate vaccine for tuberculosis and further increased
the understanding of the immunogenicity of this protein. The
IFN-γ response in humans to PE_PGRS33 protein might not
be associated with latent tuberculosis infection. In this context,
the PE_PGRS33 will not be suitable as immunological biomarker
for this condition. The IFN-γ response and the sera reactivity
to the PE_PGRS33 protein in healthy individuals is independent
of the infection with M. tuberculosis. These observations suggest
that T and B cell responses to PE_PGRS33 could be induced by
BCG vaccination and can be maintained for many years in non-
infected individuals. Additionally, the humoral immune response
against PE_PGRS33 in humans targets epitopes located in the
PGRS domain. All the findings reported here contribute to the
elucidation of the role of the PE_PGRS33 protein in the immune
response against M. tuberculosis.
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